Sorrento Therapeutics Inc. (SRNE): Price and Financial Metrics


Sorrento Therapeutics Inc. (SRNE): $1.02

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SRNE POWR Grades

  • Growth is the dimension where SRNE ranks best; there it ranks ahead of 83.36% of US stocks.
  • SRNE's strongest trending metric is Value; it's been moving up over the last 177 days.
  • SRNE ranks lowest in Stability; there it ranks in the 9th percentile.

SRNE Stock Summary

  • SRNE's price/sales ratio is 7.98; that's higher than the P/S ratio of 84.44% of US stocks.
  • The volatility of SORRENTO THERAPEUTICS INC's share price is greater than that of 87.09% US stocks with at least 200 days of trading history.
  • SORRENTO THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -74.27%, greater than the shareholder yield of merely 7% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to SORRENTO THERAPEUTICS INC, a group of peers worth examining would be SDGR, ENTX, CLXT, WATT, and DYAI.
  • Visit SRNE's SEC page to see the company's official filings. To visit the company's web site, go to www.sorrentotherapeutics.com.

SRNE Valuation Summary

  • In comparison to the median Healthcare stock, SRNE's price/sales ratio is 252.38% higher, now standing at 7.4.
  • Over the past 162 months, SRNE's price/earnings ratio has gone up 423.6.

Below are key valuation metrics over time for SRNE.

Stock Date P/S P/B P/E EV/EBIT
SRNE 2023-01-30 7.4 3.4 -0.9 -1.1
SRNE 2023-01-27 7.9 3.6 -1.0 -1.1
SRNE 2023-01-26 7.5 3.4 -0.9 -1.1
SRNE 2023-01-25 7.9 3.6 -1.0 -1.1
SRNE 2023-01-24 7.9 3.6 -1.0 -1.1
SRNE 2023-01-23 8.4 3.8 -1.0 -1.2

SRNE Growth Metrics

    The 3 year net income to common stockholders growth rate now stands at -69.03%.
  • Its 4 year revenue growth rate is now at 174.21%.
  • Its 5 year net income to common stockholders growth rate is now at -279.88%.
Over the past 33 months, SRNE's revenue has gone up $28,890,000.

The table below shows SRNE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 60.322 -297.656 -493.567
2022-06-30 54.984 -319.597 -523.794
2022-03-31 57.034 -317.124 -471.65
2021-12-31 52.904 -281.821 -428.325
2021-09-30 51.333 -250.553 -355.41
2021-06-30 51.024 -210.033 -319.63

SRNE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SRNE has a Quality Grade of D, ranking ahead of 18.46% of graded US stocks.
  • SRNE's asset turnover comes in at 0.081 -- ranking 278th of 681 Pharmaceutical Products stocks.
  • VBLT, ISEE, and CNCE are the stocks whose asset turnover ratios are most correlated with SRNE.

The table below shows SRNE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.081 0.770 -0.709
2021-03-31 0.081 0.766 -0.448
2020-12-31 0.072 0.751 -0.573
2020-09-30 0.074 0.788 -0.513
2020-06-30 0.065 0.681 -0.446
2020-03-31 0.059 0.625 -0.388

SRNE Price Target

For more insight on analysts targets of SRNE, see our SRNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.67 Average Broker Recommendation 1.5 (Moderate Buy)

SRNE Stock Price Chart Interactive Chart >

Price chart for SRNE

SRNE Price/Volume Stats

Current price $1.02 52-week high $3.60
Prev. close $1.02 52-week low $0.74
Day low $0.98 Volume 6,570,300
Day high $1.06 Avg. volume 13,236,039
50-day MA $1.07 Dividend yield N/A
200-day MA $1.68 Market Cap 481.32M

Sorrento Therapeutics Inc. (SRNE) Company Bio


Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.


SRNE Latest News Stream


Event/Time News Detail
Loading, please wait...

SRNE Latest Social Stream


Loading social stream, please wait...

View Full SRNE Social Stream

Latest SRNE News From Around the Web

Below are the latest news stories about SORRENTO THERAPEUTICS INC that investors may wish to consider to help them evaluate SRNE as an investment opportunity.

Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock

SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) held by Sorrento. These statements, which contain the account numbers and amount of Scilex dividend shares, were previously mailed out by Continental Stock Transfer & Trust Company. The dividend

Yahoo | February 4, 2023

Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation’s removal

Yahoo | February 2, 2023

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the

Yahoo | February 2, 2023

Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

SAN DIEGO, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The FAQs address questions regarding the details of the dividend, including the record date, payment date, dividend ratio, distribution of the sh

Yahoo | January 30, 2023

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

PALO ALTO, Calif., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The FAQs address questions regarding the details of the di

Yahoo | January 30, 2023

Read More 'SRNE' Stories Here

SRNE Price Returns

1-mo -10.53%
3-mo -29.66%
6-mo -60.62%
1-year -67.72%
3-year -69.00%
5-year -85.53%
YTD 15.12%
2022 -80.95%
2021 -31.87%
2020 101.92%
2019 40.83%
2018 -36.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7759 seconds.